Gateways to clinical trials

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 10, 2007, Pages 697-735

  Bayes M ^a   Rabasseda, X ^a   Prous, J R ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE BETA; ALISKIREN; AMLODIPINE; ATENOLOL; ATORVASTATIN; BOSENTAN; CATUMAXOMAB; CETUXIMAB; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EZETIMIBE; FONDAPARINUX; HYDROCHLOROTHIAZIDE; IRON; NATALIZUMAB; NICOTINIC ACID; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLACEBO; RAMIPRIL; RANOLAZINE; RECOMBINANT RELAXIN; ROSUVASTATIN; TADALAFIL; TIOTROPIUM BROMIDE; UNINDEXED DRUG; URODILATIN; VALSARTAN; VERNAKALANT;

ANEMIA; ANKYLOSING SPONDYLITIS; ASCITES TUMOR; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; CROHN DISEASE; DRUG ELUTING STENT; DRUG RESEARCH; FABRY DISEASE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEPATITIS C; HUMAN; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; OBESITY; OVARY CANCER; PARACENTESIS; PSORIASIS; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RAYNAUD PHENOMENON; RENDU OSLER WEBER DISEASE; REVIEW; RHEUMATOID ARTHRITIS; ULCERATIVE COLITIS;

CLINICAL TRIALS AS TOPIC; HUMANS; META-ANALYSIS AS TOPIC; TREATMENT OUTCOME;

EID: 39149116694     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (248)

1. Erbs, S., Beck, E.B., Linke, A. et al. Rosuvastatin treatment in patients with chronic heart failure: Impact on oxidative stress, regenerative capacity and endothelial function. Eur Heart J 2007, 28(Suppl. 1): 519.
2. Fichtlscherer, S., Schmidt-Lucke, C., Bojunga, S. et al. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: Clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J 2006, 27(10): 1182.
3. Deshpande, N.V., Mardikar, H.M., Lokare, S.A., Deo, D., Admane, P., Mardikar, M.H. Trial of atorvastatin-ezetimibe versus atorvastatin-niacin for modulation of HDL-cholesterol in Asian Indians with established coronary artery disease. Eur Heart J 2007, 28(Suppl. 1): 849.
4. Sculpher, M.J., Lozano-Ortega, G., Sambrook, J.C. et al. Cost-effectiveness in France of fondaparinux versus enoxaparin in non-ST-elevation acute coronary syndrome: An analysis using data from OASIS-5. Eur Heart J 2007, 28(Suppl. 1): 858.
5. Mikhail, G.W., Corbett, S., Grube, E. 'TAXUS WOMAN': Paclitaxel elutlng stents are equally effective in women as men - A gender specific sub-group analysis of the TAXUS II-VI trials. Eur Heart J 2007, 28(Suppl. 1): 842.
6. Dawkins, K.D., Grube, E., Guagliumi, G. et al. TAXUS VI trial: Four-year outcomes in high-risk subgroups (longer lesions, multiple overlapping stents). Eur Heart J 2007, 28(Suppl. 1): 326.
7. Scirica, B.M., Morrow, D.A., Hod, H. et al. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the metabolic efficiency with ranolazine for less ischemia in non ST-elevation Acute Coronary syndrome thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation 2007, 116(15): 1647.
8. Morice, M.C., Serruys, P.W., Barragan, P. et al. Long-term clinical outcomes with sirolimus-eluting coronary stents: Five-year results of the RAVEL trial. J Am Coll Cardiol 2007, 50(14): 1299.
9. Solinas, E., Nikolsky, E., Lansky, A. et al. Women derive similar benefit from sirolimus-eluting stenting as do men: Pooled analysis of the CYPHER randomized trials. Eur Heart J 2007, 28(Suppl. 1): 327.
10. Willich, S.N., Brueggenjuergen, B., Mcbride, D., Bode, C., Hamm, C.W., Kuck, K.H. Sirolimus-eluting versus bare-metal stents for the reduction of coronary restenosis: Outcome and economic analysis of the GERSHWIN Study. Eur Heart J 2007, 28(Suppl. 1): 508.
11. Wezenberg, E., Dartel, M., Zwiers, M., Kuilenburg, J., Pop, G., Pop-Purceleanu, M. The effect of intensive cholesterol-lowering therapy with atorvastatin and ezetimibe on neurocognitive deficits, depression and white matter lesions in elderly patients with atrial fibrillation. Eur Heart J 2007, 28(Suppl. 1): 130.
12. Stiell, I.G., Badenhorst, J.C.W., Kitt, T.M., Engel, D. A phase 3, multicenter, open-label safety study of vernakalant hydrochloride injection in patients with atrial fibrillation. Eur Heart J 2007, 28(Suppl. 1): 809.
13. Torp-Pedersen, C., Raev, D., Georgiev, P. et al. Oral vernakalant (RSD1235-SR) prevents recurrence of atrial fibrillation following cardioversion. Eur Heart J 2007, 28(Suppl. 1): 401.
14. Mitrovic, V., Seferovic, P., Moiseyev, V.S. et al. Ularitide decreases endothelin-1 in patients with decompensated heart failure. Eur J Heart Fail Suppl 2007, 6(1): Abst 478.
15. Kourea, K., Parissis, J.T., Panou, F. et al. Darbepoetin-alfa reduces plasma interleukin-6 and C-reactive protein and improves quality of life in patients with chronic heart failure and anemia. Eur J Heart Fail Suppl 2007, 6(1): Abst 662.
16. Kato, M., Komamura, K., Kitakaze, M. et al. Dual effects of novel muscarinic bronchodilator, tiotropium, on COPD and heart failure: A randomized, double blind, cross-over, placebo-controlled clinical trial. Eur Heart J 2007, 28(Suppl. 1): 52.
17. Eikelboom, J., Cohen, A.T., Turpie, A.G.G. Fondaparinux reduces symptomatic pulmonary embolism and death in patients hospitalized with congestive heart failure: A sub-analysis of the randomized ARTEMIS trial. Eur Heart J 2007, 28(Suppl. 1): 50.
18. Dschietzig, T., Unemori, E., Wood, S. et al. A pilot safety and dose-finding trial of intravenous recombinant human relaxin (rhRlx) in compensated congestive heart failure. Eur Heart J 2007, 28(Suppl. 1): 387.
19. Kaluski, E., Leitman, M., Cotter, G. Clinical and hemodynamic effects of bosentan in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension - A randomized multi-center study. Eur J Heart Fail Suppl 2007, 6(1): Abst 649.
20. Schmieder, R.E., Philipp, T., Guerediaga, J. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in patients with hypertension: A 26-week, randomized, double-blind trial. J Hypertens 2007, 25(Suppl. 2): Abst P42.343.
21. Ruilope, L.M., Anderson, D.R., Arora, V., Bush, C., Keefe, D.L. Aliskiren, a direct renin inhibitor (DRI), provides smooth, sustaines 24-h blood pressure control as monotherapy or in combination with valsartan or ramipril in patients with hypertension. Eur Heart J 2007, 28(Suppl. 1): 868.
22. Lindgren, P., Buxton, M., Kahan, T. et al. Amlodipine plus atorvastatin is cost-effective compared to atenolol + atorvastatin, amlodipine or atenolol alone: The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Eur Heart J 2007, 28(Suppl. 1): 857.
23. Grander, W., Eller, P., Fuschelberger, R., Tilg, H. Bosentan treatment of portopulmonary hypertension related to liver cirrhosis owing to hepatitis C. Eur J Clin Invest 2006, 36(Suppl. 3): 67.
24. Ahmadi-Simab, K., Hellmich, B., Gross, W.L. Bosentan for severe pulmonary arterial hypertension related to systemic sclerosis with interstitial lung disease. Eur J Clin Invest 2006, 36(Suppl. 3): 44.
25. Giannelli, G., Iannone, F., Marinosci, F., Lapadula, G., Antonaci, S. Clinical outcomes of bosentan in pulmonary arterial hypertension do not correlate with levels of TIMPs. Eur J Clin Invest 2006, 36(Suppl. 3): 73.
26. Cozzi, F., Montisci, R., Marotta, H. et al. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases. Eur J Clin Invest 2006, 36(Suppl. 3): 49.
27. Seyfarth, H.J., Hammerschmidt, S., Pankau, H., Winkler, J., Wirtz, H. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007, 74(3): 287.
28. Galie, N., Rubin, L.J., Hoeper, M.M. et al. Bosentan improves hemodynamics and delays time to clinical worsening in patients with mildly symptomatic pulmonary arterial hypertension (PAH): Results of the EARLY study. Eur Heart J 2007, 28(Suppl. 1): 140.
29. Stähler, G., von Hunnius, P. Successful treatment of portopulmonary hypertension with bosentan: Case report. Eur J Clin Invest 2006, 36(Suppl. 3): 62.
30. Denton, C.P., Gabrielli, A., Peter, H., Pope, J.E., Guillevin, L. Long-term effects of bosentan on quality of life (QOL) and survival in patients with pulmonary arterial hypertension (PAH) associated with connective tissue disease (CTD): A subgroup analysis of patients with digital ulcers. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0264.
31. Jordan, J., Boye, S.W., Le Breton, S., Keefe, D.L. The direct renin inhibitor aliskiren effectively lowers blood pressure in obese patients with hypertension who are non-responsive to hydrochlorothiazide monotherapy. J Hypertens 2007, 25(Suppl. 2): Abst P21.151.
32. Sandorfi, N., Jimenez, S.A. Treatment of digital ulceration due to Raynaud's phenomenon (RP) with long acting phosphodiesterase 5 (PDE5) inhibitor: Tadalafil. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0317.
33. Bonderman, D., Nowotny, R., Skoro-Sajer, N., Adlbrecht, C., Lang, I.M. Bosentan therapy for pulmonary arterial hypertension associated with hereditary haemorrhagic telangiectasia. Eur J Clin Invest 2006, 36(Suppl. 3): 71.
34. Lubanda, J.C., Palecek, T., Kuchynka, P. et al. The effect of Agalsidase-Beta therapy on left ventricular structure and function in patients with Fabry disease: A prospective echocardiographic study. Eur Heart J 2007, 28(Suppl. 1): 476.
35. Parsons, S.L., Kutarska, E., Koralewski, P. et al. Treatment of ovarian cancer patients with malignant ascities using the trifunctional antibody catumaxomab: Results of a phase II/III study. J Clin Oncol 2007, 25(18, Suppl.): Abst 5520.
36. Hitre, E., Boer, A., Remenar, E. et al. Preliminary results of a phase II trial on targeted therapy with cetuximab in EGFR-expressing adenoid cystic carcinoma of the oral cavity. Ann Oncol 2006, 17(Suppl. 9): Abst 612.
37. Panaccione, R., Feagan, B.G., Fedorak, R. Natalizumab induces sustained response and remission in patients with Crohn's disease activity index scores greater than or equal to 330: Results from the ENCORE trial. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1289.
38. Tang, B., Rahman, M., Stephenson, J. et al. The impact of antitumor necrosis factors on healthcare costs in patients with immune mediated inflammatory disease. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0480.
39. Scherzer, T.-M., Staufer, K., Gurguta, C., Novacek, G., Ferenci, P., Vogelsang, H. Antiviral treatment in Crohn's patients with chronic hepatitis C is well tolerated and effective. Gastroenterology 2007, 132(4, Suppl. 2): Abst W1150.
40. Fuss, I.J., Becker, C., Yang, Z. et al. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis 2006, 12(1): 9.
41. Simsek, H., Schiff, E., Goodman, Z., Brett-Smith, H., Klesczewski, K., Kreter, B. Efficacy of entecavir and lamivudine in chronic hepatitis B patients with advanced fibrosis/cirrhosis. J Hepatol 2007, 46(Suppl. 1): Abst 518.
42. Hatemi, G., Tascilar, K., Yurdakul, S., Ozdogan, H. Tumor necrosis factor alpha antagonists in the treatment of secondary amyloidosis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0391.
43. Pirozynski, M., Czech, M., Pachocki, R. Short term cost-effectiveness of fenspiride in chronic bronchitis in Poland. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A640.
44. Li, J., Zhao, H., Si, C.-W. et al. Predictors of response in patients with HBeAg-positive chronic hepatitis B using adefovir dipivoxil therapy. J Hepatol 2007, 46(Suppl. 1): Abst 524.
45. Bain, V.G., Yoshida, E.M., Kaita, K.D. et al. Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res 2006, 35(4): 256.
46. Balan, V., Nelson, D.R., Sulkowski, M.S. et al. Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C. Antivir Ther 2006, 11(7): 901.
47. Neumann, A.U., Rozenberg, L., Zeuzem, S. et al. Albumin interferon alfa-2b dosed at Q2w or Q4w intervals demonstrates comparable week 12 efficacy response in IFN naive, genotype-1 rapid viral responders. J Hepatol 2007, 46(Suppl. 1): Abst 624.
48. Zehnter, E., Mauss, S., Boeker, K. et al. Potential relevance of rapid viral response for SVR and optimisation of the treatment of hepatitis C (CHC) with peg-interferon alpha-2a (PEG) and ribavirin (RBV). J Hepatol 2007, 46(Suppl. 1): Abst 657.
49. Berak, H., Kolakowska-Rzadzka, A., Wasilewski, M. Randomized, open label trial comparing efficacy and safety of pegylated interferon alfa 2b vs alfa 2b treatment of patients with chronic hepatitis C infected with non 2/3 genotypes - Final analysis. J Hepatol 2007, 46(Suppl. 1): Abst 572.
50. Marcellin, P., Hadziyannis, S.J., Zeuzem, S. et al. Host and viral baseline characteristics in hepatitis C naive and non-responder patients: Comparison of three large randomised multinational trials. J Hepatol 2007, 46(Suppl. 1): Abst 614.
51. Berak, H., Kolakowska-Rzadzka, A., Wasilewski, M. et al. Comparison of efficacy of treatment with peginterferon alfa plus ribavirin among patients chronically infected with non 2/3 HCV genotypes with low and high viremia. J Hepatol 2007, 46(Suppl. 1): Abst 574.
52. Torres-Ibarra, R., Cano-Dominguez, C. Sustained virological response after more than three years of the end of treatment with conventional alpha-2b or pegylated alpha-2a interferon. J Hepatol 2007, 46(Suppl. 1): Abst 652.
53. Rockstroh, J.K., Ahlenstiehl, G., Vogel, M. et al. The influence of nucleoside free HAART on the treatment of chronic hepatitis C with pegylated interferon/ribavirin combination treatment. J Hepatol 2007, 46(Suppl. 1): Abst 636.
54. Shiha, G., Khalek, E.A., Abbas, B., Elshennawy, H., Zalata, K.H. Sustained virological response of peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus genotype 4. J Hepatol 2007, 46(Suppl. 1): Abst 565.
55. Witthoeft, T., Fuchs, M. Peg-IFN alpha-2a plus ribavirin is superior compared to high dose consensus interferon (CIFN) and ribavirin in the treatment of patients with chronic hepatitis C. J Hepatol 2007, 46(Suppl. 1): Abst 655.
56. Baiocchi, L., Longhi, C., Monache, M.D. et al. The extent of ribavirin-induced haemolysis during treatment for hepatitis C is unrelated to administered dose, rather depends on baseline haemoglobin level and drug erythrocyte concentration. J Hepatol 2007, 46(Suppl. 1): Abst 527.
57. Basso, M., Torre, F., Blanchi, S., Delfino, A., Picciotto, A. Long-term virological follow-up of patients with chronic hepatitis C who obtained a sustained virological response after treatment with pegylated interferon and ribavirin. J Hepatol 2007, 46(Suppl. 1): Abst 528.
58. Gramenzi, A., Margotti, M., Balsano, C. et al. Ketoprofen plus PEG-IFN alpha-2a and ribavirin as a triple treatment for genotype 1 (G1) chronic hepatitis C (CHC): Results of a phase II randomized controlled trial. J Hepatol 2007, 46(Suppl. 1): Abst 611.
59. Pockros, P., Rodrigues-Torres, M., Lurie, Y. et al. Impact of taribavirin exposure of efficacy, anemia rates, and G1 side effects when used with pegylated interferon alpha-2b for the treatment of chronic hepatitis C. J Hepatol 2007, 46(Suppl. 1): Abst 632.
60. Ghosn, J., Quinson, A.M., Sabo, N. et al. Antiviral activity of low-dose alovudine in antiretroviral-experienced patients: Results from a 4-week randomized, double-blind, placebo-controlled dose-ranging trial. HIV Med 2007, 8(3): 142.
61. Margolis, D.M., Mukherjee, A.L., Fletcher, C.V. et al. The use of beta-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection. AIDS 2007, 21(15): 2025.
62. Thio, B.M.K.S., De Vries, F., Egberts, T.C.G., Leufkens, H.G.M., Van Staa, T.P. Use of selective serotonin reuptake inhibitors and risk of hip/femur fractures: A population-based case-control study. Calcif Tissue Int 2007, 80(Suppl. 1): Abst OC013.
63. Melchiorre, D., Nacci, F., Sacu, O. et al. Teriparatide is effective in reducing pain and improving quality of life in the first six months of treatment in glucocorticoid-induced osteoporosis in multi-fractured patients. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0326.
64. Maccubbin, D., Sirah, W., Betteridge, A. et al. Lipid-altering efficacy and tolerability profile of extended release niacin/laropiprant in patients with primary hypercholesterolemia or mixed hyperlipidemia. Eur Heart J 2007, 28(Suppl. 1): 108.
65. Yoshitomi, Y., Ishii, T., Kaneki, M. et al. Efficacy of a low dose of pravastatin compared with atorvastatin in primary hyperlipidemia: Results of a 12-week, open label study. J Atheroscler Thromb 2006, 13(2): 108.
66. Tran, Y.B., Frial, T., Miller, P.S. Statin's cost-effectiveness: A Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol 2007, 14(2): e205.
67. Becker, M.A., MacDonald, P.A., Lloyd, E.J., Lademacher, C., Joseph-Ridge, N. Urate-lowering pharmacotherapy with febuxostat or allopurinol in black-American subjects with gout. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0340.
68. Becker, M.A., Schumacher, H.R., MacDonald, P.A. et al. Urate-lowering therapy in subjects with gout: Interim results from the febuxostat/allopurinol comparative extension long-term study (EXCEL). Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0339.
69. Misiorowski, W. Cinacalcet (Mipara, Amgen) is more effective than bisphosphonates at controlling hypercalcemia in patients with parathyroid carcinoma: A case study. Endocr Abstr 2007, 14: Abst P416.
70. Kastelein, J.J.P., Bradley, J., Chuang, E. et al. Effect of dose and dose schedule on the efficacy and safety of an antisense inhibitor of apoB in volunteers with mild hypercholesterolemia. Atheroscler Suppl 2006, 7(3): Abst Th-P16:268.
71. Binbrek, A.S., Elis, A., Al-Zaibag, M. et al. Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY alpha study). Curr Ther Res 2006, 67(1): 21.
72. Quarta, C., Potena, L., Grigioni, F. Safety and efficacy of ezetimibe with low-doses of simvastatin in heart transplant recipients. Eur Heart J 2007, 28(Suppl. 1): 352.
73. Hassett, A.L., Li, T., Buyske, S., Savage, S.V., Maclean, J.R., Gignac, M.A.M. Multidimensional assessment of independence in patients with rheumatoid arthritis: Data from the ATTAIN study database. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0491AHP.
74. Dougados, M., Keiserman, M., Codding, C. et al. Efficacy of abatacept of infliximab treatment in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a 1-year double-blind, randomized, placebo-controlled trial. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0118.
75. Schiff, M., Pritchard, C., Teng, J., Bahrt, K., Genovese, M. The safety of abatacept in patients with active rheumatoid arthritis and an inadequate response to anti-TNF therapy: Results from the ARRIVE trial. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0121.
76. Dougados, M., Russell, A., Li, T. et al. Abatacept reduces fatigue and pain severity and sleep problems through 2 years in rheumatoid arthritis patients in the AIM and ATTAIN trials. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0005.
77. Karanikolas, G.N., Karras, D., Lambropoulos, A. et al. Anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with conventional immunosuppressive dmards, for severe rheumatoid arthritis: Final results of the grass (Greek anakinra assessment) study. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0010.
78. Ikonomidis, I., Nikolaou, M., Paraskevaidis, I. et al. Inhibition of interleukin-1 activity by anakinra improves left ventricular function: A randomized cross-over, placebo-controlled, trial. Eur Heart J 2007, 28(Suppl. 1): 144.
79. Cohen, S.B., Valen, P.A., Ritchlin, C. et al. Inhibiting RANKL with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: 6-month MRI results from a randomized, placebo-controlled study. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0226.
80. Dabbous, O., Lee, M., Rambharose, J. et al. Persistency among anti-tumor necrosis factors in the treatment of rheumatoid arthritis from a payor perspective. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0429.
81. Tang, B., Dabbous, O., Meissner, B., Thompson, H., Rahman, M. Comparison of therapeutic persistence among anti-tumor necrosis factors in the treatment of rheumatoid arthritis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0482.
82. Perez-Zafrilla, B., Carmona, L., Descalzo, M.A., Gomez-Reino, J.J. Administration related reactions with anti-TNFs are varied, can appear at any time of the treatment and up to 14 days after administration. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0192.
83. Tang, B., Rahman, M., Stephenson, J., Quimbo, R., Dabbous, O., Thompson, H. The association between co-existing immune mediated inflammatory diseases (IMID) and healthcare costs in patients with rheumatoid arthritis (RA) who received anti-tumor necrosis factors (anti-TNFs). Ann Rheum Dis 2007, 66(Suppl. 2): Abst AB0916.
84. Massara, A., Govoni, M., Trotta, F. High incidence of serious adverse events among elderly rheumatoid patients receiving monoclonal antibodies anti-TNFalpha. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0184.
85. Payet, S., Francesconi, C., Franca, L.R., Boissier, M., Launois, R. Budget impact of rituximab (MabThera) after failure of one or more TNF inhibitor therapies in the treatment of rheumatoid arthritis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0024.
86. Schach, S., Rubbert, A., Kielhorn, A. Cost-benefit comparison of biologic DMARDS using a non-modelling approach. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0028.
87. Salliot, C., Gossec, L., Dougados, M. Rituximab, abatacept and anakinra do not increase the risk of serious infections: A metaanalysis of published randomised controlled trials. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0027.
88. Hashimoto, J., Garnero, P., Miyasaka, N. et al. Humanized antiinterleukin-6 receptor antibody (Tocilizumab) is effective in suppression of radiographic, progression in patients with early rheumatoid arthritis, regardless of baseline levels of the predictors: SAMURAI study. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0122.
89. Nishimoto, N., Miyasaka, N., Yamamoto, K. et al. Long-term safety and efficacy of tocilizumab (an anti-IL-6 receptor monoclonal antibody) in monotherapy, in patients with rheumatoid arthritis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0227.
90. Ruperto, N., Giannini, E.H., Prieur, A.M. et al. Efficacy and safety of abatacept a co-stimulation modulator, in children and adolescents with active juvenile idiopathic arthritis: Results of double-blind withdrawal phase. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0116.
91. Lovell, D.J., Ruperto, N., Prieur, A.-M. et al. Assessment of open label co-stimulation blockade with abatacept in children and adolescents with active juvenile idiopathic arthritis (JIA). Arthritis Rheum 2006, 54(9, Suppl.): Abst 719.
92. Ruperto, N., Giannini, E.H., Quartier, P. et al. Re-establishment of clinical benefit in patients with juvenile idiopathic arthritis in whom abatacept, a co-stimulation modulator, had been withdrawn for up to 6 months and then re-introduced. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0026.
93. Katsicas, M.M., Russo, R.A. Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and infliximab. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0403.
94. Lequerre, T., Quartier, P., Rosellini, D. et al. Efficacy and safety of anakinra (kineret) in patients with systemic onset juvenile idiopathic arthritis (SoJIA) and adult onset Still's disease (AoSD): Follow up of 16 months - Study of the Societe francophone pour la rhumatologie et les maladies inflammato. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0399.
95. Imagawa, T., Ozawa, R., Miyamae, T. et al. Efficacy and safety in 48-week treatment of tocilizumab in children with polyarticular course juvenile idiopathic arthritis with polyarticular or oligoarticular onset. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0398.
96. Yokota, S., Imagawa, T., Mori, M. et al. Efficacy and safety of tocilizumab in 48-week treatment in children with systemic juvenile idiopathic arthritis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0184.
97. Nestorov, I., Rossi, C.P., Munafo, A. et al. Pharmacokinetics and biological activity of atacicept after intravenous and subcutaneous administration to SLE patients. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0021.
98. Furie, R., Lisse, J., Merrill, J.T. et al. Belimumab (fully human monoclonal antibody to B-lymphocyte stimulator [BLyS] improves or stabilizes SLE activity in a multicenter phase 2 trial. Arthritis Rheum 2006, 54(9, Suppl.): Abst 535.
99. Devogelaer, J.P., Roux, C., Isaia, G. et al. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. J Bone Miner Res 2007, 22(Suppl. 1): Abst T412.
100. Roux, C., Isaia, G., Andia, J.B.C., Devogelaer, J. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis 2007, 66(Suppl. 2): Abst LB0005.
101. Reginster, J.Y., Brixen, K., Cormier, C., Cannata Andia, J.B. Long term efficacy of strontium ranelate in reducing the risk of vertebral and non-vertebral including hip fractures in post menopausal osteoporotic women over 5 years. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0158.
102. Bruyere, O., Delferriere, D., Roux, C., Fechtenbaum, J., Kolta, S., Reginster, J. Y. Positive effects of strontium ranelate on spine osteoarthritis progression. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0025.
103. Gladman, D., Mease, P., Choy, E., Sasso, E. Relationship between C-reactive protein (CRP) concentration and joint damage in psoriatic arthritis (PSA): Subanalysis of placebo- and adalimumab-treated patients in ADEPT. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0148.
104. Van Den Bosch, F., Manger, B., Goupille, P. et al. Adalimumab (Humira) is effective in treating patients with psoriatic arthritis (PSA) in real-life clinical practice: Results of the STEREO trial. Ann Rheum Dis 2007, 66(Suppl. 2): Abst OP0147.
105. Van Der Heijde, D. Adalimumab treatment maintains efficacy and safety in patients with ankylosing spondylitis (AS)-2-year results from ATLAS. Ann Rheum Dis 2007, 66(Suppl. 2): Abst FRI0440.
106. Carrasco, J.A., Martos, J., Perez-Guijo, V. et al. Adalimumab achieve significant improvement in active ankylosing spondylitis patients assessed by magnetic resonance imaging. Ann Rheum Dis 2007, 66(Suppl. 2): Abst FRI0370.
107. Lopez-Olivo, M.A., Suarez-Almazor, M.E., Moffett, M.L. Economic evaluation of biologic therapies in ankylosing spondylitis: A systematic review. Ann Rheum Dis 2007, 66(Suppl. 2): Abst THU0479.
108. Dragovich, T., Mendelson, M., Modiano, M. et al. Phase I study of Amplimexon (Imexon, inj.) in patients with advanced solid tumors and lymphomas: Final report. Eur J Cancer Suppl 2006, 4(12): Abst 432.
109. Oaknin, A., Plummer, R., Salazar, R. Phase I combination study of plitidepsin and carboplatin in advanced solid tumors. J Clin Oncol 2007, 25(18, Suppl.): Abst 2558.
110. Geoerger, B., Doz, F., Estlin, E. et al. Clinical phase I-II and pharmacokinetic study of plitidepsin in children with malignant tumors. Eur J Cancer Suppl 2006, 4(12): Abst 248/249.
111. Zhang, J., Chung, K., Zergebel, C., Urrea, P., Quinones, M., Saltz, L. Phase I study of oral S-1 in combination with oxaliplatin (oxali) and bevacizumab (bev) in patients with advanced solid tumors. J Clin Oncol 2007, 25(18, Suppl.): Abst 4091.
112. Schilsky, R.L., Geary, D., Skoog, L. et al. Phase I and pharmacokinetic (PK) study of PTK787/ZK222584 (PTK/ZK) plus capecitabine (cape) in patients (pts) with advanced cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 3595.
113. Clark, J.W., Meyerhardt, J.A., Sahani, D.V. et al. Phase II study of gemcitabine, oxaliplatin in combination with bevacizumab (GEMOX-B) in patients with unresectable or metastatic biliary tract and gallbladder cancers. J Clin Oncol 2007, 25(18, Suppl.): Abst 4625.
114. Li, S., Dreicer, R., Roth, B., Manoloa, J., Cooney, M., Wilding, G. Phase II trial of pemetrexed disodium and gemcitabine in advanced carcinoma of the urothelium (E4802): A trial of the eastern cooperative oncology group. J Clin Oncol 2007, 25(18, Suppl.): Abst 5079.
115. Kirkpatrick, J., Desjardins, A., Quinn, J. et al. Phase II open-label, safety, pharmacokinetic and efficacy study of 2-methoxyestradiol nano crystal colloidal dispersion administered orally to patients with recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(18, Suppl.): Abst 2065.
116. Raval, S., Hwang, S., Dorsett, L. et al. Bevacizumab and irinotecan in patients (pts) with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007, 25(18, Suppl.): Abst 2078.
117. De Groot, J.F., Gilbert, M.R., Hess, K.R. et al. Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. J Clin Oncol 2007, 25(18, Suppl.): Abst 2024.
118. Sathornsumetee, S., Rich, J.N., Vredenburgh, J.J. et al. Phase I trial of imatinib mesylate, hydroxyurea and vatalanib for patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 2007, 25(18, Suppl.): Abst 2027.
119. Batchelor, T., Sorensen, A.G., Ancukiewicz, M. et al. A phase II trial of AZD2171 (cediranib), an oral pan-VEGF receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2007, 25(18, Suppl.): Abst 2001.
120. Dresemann, G., Hosius, C., Nikolova, Z., Letvak, L. Single center phase II trial analysing the role of imatinib/hydroxyurea in patients (pts) with pretreated non-progressive glioblastoma (GBM) as maintenance treatment. J Clin Oncol 2007, 25(18, Suppl.): Abst 2055.
121. Mohile, N.A., Abrey, L.E., Lymberis, S.C. et al. A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas. J Clin Oncol 2007, 25(18, Suppl.): Abst 2028.
122. Bota, D.A., Desjardins, A., Quinn, J.A. et al. Phase II trial of imatinib mesylate and hydroxyurea for adults with recurrent/progressive low-grade glioma. J Clin Oncol 2007, 25(18, Suppl.): Abst 2053.
123. Kang, T., Jin, T., Peereboom, D. Irinotecan and bevacizumab in progressive primary brain tumors: The Cleveland clinic experience. J Clin Oncol 2007, 25(18, Suppl.): Abst 2077.
124. Phuphanich, S., Chamberlain, M., Mikkelsen, T. et al. A phase I study of SDX-102 for the treatment of patients with MTAP-deficient recurrent malignant gliomas. J Clin Oncol 2007, 25(18, Suppl.): Abst 2063.
125. Bode, U., Buchen, S., Warmuth-Metz, M., Pietsch, T., Bach, F., Fleischhack, G. Final report of a phase II trial of nimotozumab in the treatment of refractory and relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2007, 25(18, Suppl.): Abst 2006.
126. Robins, H.I., Wen, P. Y., Chang, S.M. et al. Phase I study of erlotinib and CCI-779 (temsirolimus) for patients with recurrent malignant gliomas (MG) (NABTC 04-02). J Clin Oncol 2007, 25(18, Suppl.): Abst 2057.
127. Denduluri, N., Berman, A.W., Vatas, U., Chow, C.K., Rosing, D.R., Swain, S.M. Cardiotoxicity after doxorubicin and AZD2171, an oral vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor, in patients (pts) with breast cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 554.
128. Romieu, G., Clemens, M., Mahlberg, R. et al. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial. Crit Rev Oncol Hematol 2007, 64(1): 64.
129. Blasinska-Morawiec, M., Martin, M., Salas, F. et al. A phase II study of pemetrexed and doxorubicin in patients with advanced or metastatic breast cancer (MBC). J Clin Oncol 2007, 25(18, Suppl.): Abst 1047.
130. Link, J.S., Waisman, J.R., Nguyen, B., Jacobs, C.I. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 1101.
131. Schmid, P., Regierer, A., Kiewe, P. et al. Bortezomib and capecitabine in patients with metastatic breast cancer previously treated with taxanes and/or anthracyclines: Final results of a phase I/II study. J Clin Oncol 2007, 25(18, Suppl.): Abst 1072.
132. Sledge, G., Miller, K., Moisa, C., Gradishar, W. Safety and efficacy of capecitabine (C) plus bevacizumab (B) as first-line in metastatic breast cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 1013.
133. Wang, M., Gradishar, W.J., Sparano, J.A., Perez, E.A., Sledge, G. A phase II trial of capecitabine (C) in combination with the farnesyltransferase (FT) inhibitor (FT), tipifarnib (T), in patients (pt) with metastatic breast cancer (MBC): ECOG trial 1103. J Clin Oncol 2007, 25(18, Suppl.): Abst 1036.
134. Dennison, S.K., Jacobs, S.A., Wilson, J. et al. A phase II clinical trial of ZD1839 (gefitinib) in combination with docetaxel as first-line treatment in patients with advanced breast cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 1059.
135. Jakobs, T.F., Hoffmann, R.-T., Tatsch, K., Reiser, M.F. Radioembolization for hepatic metastases from breast cancer: Initial results. J Vasc Interv Radiol 2007, 30(1, Part 2): Abst 405.
136. Kvols, L., Glusman, J.E., Hahn, E.A. et al. The effects of pasireotide (SOM230) on health-related quality of life in patients with metastatic carcinoid tumors refractory or resistant to octreotide LAR. J Clin Oncol 2007, 25(18, Suppl.): Abst 4558.
137. Rischin, D., Narayan, K., Oza, A. et al. A phase I study of
138. Giuliani, F., De Vita, F., Lorusso, V. et al. Bevacizumab plus folfiri as first-line therapy in advanced colorectal cancer: A multicenter phase II study of the Gruppo Oncologico Dell'Italia meridionale (PROT. GOIM 2601). Ann Oncol 2007, 18(Suppl. 6): Abst.
139. Ramanathan, R.K., Rajasenan, K., Crandall, T. et al. Phase II study of the A-ICOX regimen bevacizumab (Bev), weekly intermittent capecitabine (Cap) and oxaliplatin (Ox) for untreated advanced colorectal cancer (CRC). J Clin Oncol 2007, 25(18, Suppl.): Abst 4092.
140. Maughan, T. Cetuximab (C), oxaliplatin (Ox) and fluoropyrimidine (Fp): Toxicity during the first 12 weeks of treatment for the first 804 patients entered into the MRC COIN (CR 10) trial. J Clin Oncol 2007, 25(18, Suppl.): Abst 4070.
141. Gladkov, O., Manikhas, G., Biakhov, M. et al. Phase 1 study of picoplatin (pico) in combination with 5-fluorouracil (FU) and leucovorin (LV) as initial therapy in subjects with metastatic colorectal cancer (CRC). J Clin Oncol 2007, 25(18, Suppl.): Abst 14510.
142. Hamaguchi, T., Shirao, K., Moriya, Y. et al. Adjuvant chemotherapy with uracil-tegafur (UFT) for stage III colorectal cancer: Final results of randomized trials by the national surgical adjuvant study of colorectal cancer (NSAS-CC). J Clin Oncol 2007, 25(18, Suppl.): Abst 4049.
143. Saunders, M., Van Cutsem, E., Wilson, R. et al. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: An open-label, multicenter phase I study. J Clin Oncol 2007, 25(18, Suppl.): Abst 4085.
144. Fakih, M.G., Pendyala, L., Smith, P. et al. A phase I study of vorinostat (suberoylanilide hydroxamic acid) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC). J Clin Oncol 2007, 25(18, Suppl.): Abst 4088.
145. Ocean, A.J., O'Brien, K., Lee, J. et al. Phase II trial of FOL-FOX6, bevacizumab and cetuximab in patients with colorectal cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4075.
146. Kopetz, S., Glover, K.Y., Eng, C. et al. Phase II study of infusional 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for metastatic colorectal cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4089.
147. Humblet, Y., Peeters, M., Gelderblom, H. et al. Cetuximab dose-escalation in patients (pts) with metastatic colorectal cancer (mCRC) with no or slight skin reactions on standard treatment: Pharmacokinetic (PK), pharmacodynamic (PD) and efficacy data from the EVEREST study. Eur J Cancer Suppl 2007, 5(4): Abst 3017.
148. Moehler, M., Sprinzl, M.F., Abdelfatah, M. et al. Irinotecan/ capecitabine with or without bevacizumab in metastatic colorectal cancer: Results of a prospective open-label phase IV trial. Ann Oncol 2007, 18(Suppl. 9): Abst 44P.
149. Bennouna, J., Faroux, R., Francois, E. et al. CETUFTIRI, a new combination of UFT with leucovorin (LV), irinotecan and cetuxi mab as first-line treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Preliminary results from a multicenter phase II trial. J Clin Oncol 2007, 25(18, Suppl.): Abst 4087.
150. Gruenberger, T., Tamandl, D., Puhalla, H. et al. Bevacizumab plus XELOX as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4064.
151. Gruenberger, B., Scheithauer, W., Tamandl, D. et al. Effectiveness of neoadjuvant chemotherapy including bevacizumab in patients with resectable colorectal cancer liver metastases. J Clin Oncol 2007, 25(18, Suppl.): Abst 4060.
152. Nimeiri, H.S., Faoro, L., Oza, A.M. et al. Molecular correlates (EGFR status) and plasma VEGF levels associated with a phase II study of bevacizumab plus erlotinib (BE) for patients with recurrent ovarian cancer (OC) and fallopian tube (FT) cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 5554.
153. Herzog, T.J., Spirtos, N.M., Hines, J.F. et al. Preliminary safety and efficacy results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol 2007, 25(18, Suppl.): Abst 5518.
154. Makhija, S., Glenn, D., Ueland, F. et al. Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 5507.
155. EI-Khoueiry, A.B., Rankin, C., Lenz, H.J., Philip, P., Rivkin, S.E., Blanke, C.D. SWOG 0514: A phase II study of sorafenib (BAY 43-9006) as single agent in patients (pts) with unresectable or metastatic gallbladder cancer or cholangio-carcinomas. J Clin Oncol 2007, 25(18, Suppl.): Abst 4639.
156. Neville, N.G., Kloepfer, P., Bevan, P. et al. Update of survival data for two phase II studies with monoclonal antibody cG250 (Rencarex) in combination with IL-2 or IFN alpha-2a in metastatic renal cell cancer patients. J Urol 2007, 177(4, Suppl.): Abst 909.
157. Garcia, J.A., Rini, B.I., Mekhail, T. et al. A phase II trial of low-dose interleukin-2 (IL-2) and bevacizumab in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007, 25(18, Suppl.): Abst 5103.
158. Merchan, J.R., Liu, G., Fitch, T. et al. Phase I/II trial of CCI-779 and bevacizumab in stage IV renal cell carcinoma: Phase I safety and activity results. J Clin Oncol 2007, 25(18, Suppl.): Abst 5034.
159. Sridhar, S.S., Hotte, S.J., Mackenzie, M.J. et al. Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH phase II consortium. J Clin Oncol 2007, 25(18, Suppl.): Abst 5093.
160. Drabkin, H.A., Figlin, R.A., Stadler, W.M. et al. The advanced renal cell carcinoma sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. J Clin Oncol 2007, 25(18, Suppl.): Abst 5041.
161. Jaszewski, B., Gao, X., Reddy, P. et al. Cost effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma in Canada. J Clin Oncol 2007, 25(18, Suppl.): Abst 5111.
162. Bracarda, S., Porta, C., Boni, C. et al. Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-alphala (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC study 0681. J Clin Oncol 2007, 25(18, Suppl.): Abst 5100.
163. Feldman, D.R., Kondagunta, G.V., Ronnen, E.A. et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007, 25(18, Suppl.): Abst 5099.
164. Gore, M.E., Porta, C., Oudard, S. et al. Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007, 25(18, Suppl.): Abst 5010.
165. Chedid, A., Bobrie, G., Medioni, J., Oudard, S., Azizi, M., Plouin, P.F. Blood pressure increases in ail patients given sunitinib: A teletransmitted home blood pressure study. J Hypertens 2007, 25(Suppl. 2): Abst 1C.6,
166. Malka, D., Dromain, C., Farace, F. et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): Preliminary results of a phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007, 25(18, Suppl.): Abst 4570.
167. Sun, W., Haller, D.G., Mykulowycz, K. et al. Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. J Clin Oncol 2007, 25(18, Suppl.): Abst 4574.
168. Louafi, S., Hebbar, M., Rosmorduc, O. et al. Gemcitabine, oxaliplatin (GEMOX) and cetuximab for treatment of hepatocellular carcinoma (HCC): Results of the phase II study ERGO. J Clin Oncol 2007, 25(18, Suppl.): Abst 4594.
169. Gulec, S.A. et al. Y-90 resin microsphere selective internal radiation treatment in primary and metastatic liver cancer: Objective response and therapeutic ratio analysis. HPB Suppl 2007, 9(1): Abst 62.
170. 2 combined with carboplatin and paclitaxel in non-small cell lung cancer. J Thorac Oncol 2007, 2(8, Suppl. 4): Abst P3-116.
171. McKeage, M. Phase Ib/II study of DMXAA combined with carboplatin and paclitaxel in non-small cell lung cancer (NSCLC). J Clin Oncol 2006, 24(18, Suppl.): Abst 7102.
172. Tamura, K., Nishiwaki, Y., Tamura, T. et al. A phase II study of the HER1/EGFR tyrosine kinase inhibitor (TKI), erlotinib, in Japanese patients with non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy. Ann Oncol 2006, 17(Suppl. 9): Abst 741P.
173. Zhang, X.T., Li, L.Y., Wang, S.L., Li, J.R. Gefitinib monotherapy as first-line treatment in patients with advanced NSCLC. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A873.
174. Laskin, J.J., Chi, K., Melosky, B. et al. Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as firstline treatment for patients with stage IIB/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2006, 24(18, Suppl.): Abst 17078.
175. Vansteenkiste, J., Zielinski, M., Linder, A. et al. Activity of MAGE-A3 cancer immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC): Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study. J Thorac Oncol 2007, 2(8, Suppl. 4): Abst B1-05.
176. Takiguchi, Y., Masuda, N., Seto, T. et al. Second-line chemotherapy with amrubicin for sensitive/refractory recurrent small-cell lung cancer (SCLC): A phase II study (No. 0301) by the thoracic oncology research group. Ann Oncol 2006, 17(Suppl. 9): Abst 735PD.
177. Janne, P.A., Wang, X.F., Krug, L.M., Hodgson, L., Vokes, E.E., Kindler, H.L. Phase II trial of sorafenib (BAY 43-9006) in malignant mesothelioma: CALGB 30307. Ann Oncol 2006, 17(Suppl. 9): Abst 723PD.
178. White, M.J., O'Gorman, R.L., Charles-Edwards, E.M. et al. Parametric mapping of the hepatic perfusion index with gadolinium-enhanced volumetric MRI. Br J Radiol 2007, 80(950): 113.
179. Meranze, S.G. et al. Phase II clinical trial of Yttrium-90 resin microspheres for the treatment of metastatic neuroendocrine tumor. J Vasc Interv Radiol 2007, 18(1, Part 2): Abst 422.
180. Bilbao, J.I., Martinez-Cuesta, A., Alonso-Burgos, A. et al. Liver radioembolisation (RE) with Y90 loaded resin microspheres: Results in 93 patients in a single institution. Cardiovasc Intervent Radiol 2007, 30(Suppl. 1): Abst 1303.3.
181. Jakobs, T.F., Hoffmann, R., Tatsch, K., Reiser, M. Radioembolization for hepatic metastases from breast cancer: Initial results. Cardiovasc Intervent Radiol 2007, 30(Suppl. 1): Abst 2006.5.
182. Aloia, T., Levi, F., Wicherts, D.A. et al. Hepatic resection following rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007, 25(18, Suppl.): Abst 4061.
183. Yao, J.C., Phan, A., Chang, D.Z. et al. Phase II study of RAD001 (everolimus) and depot octreotide (sandostatin LAR) in advanced low grade neuroendocrine carcinoma (LGNET). J Clin Oncol 2007, 25(18, Suppl.): Abst 4503.
184. Hobday, T.J., Rubin, J., Holen, K. et al. MCO44h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study. J Clin Oncol 2007, 25(18, Suppl.): Abst 4504.
185. Landen, C.N., Jr., Coleman, R., Milam, M.R. et al. A phase I trial of the proteosome inhibitor PS-341 in combination with carboplatin in platinum and taxane resistant ovarian cancer patients. J Clin Oncol 2007, 25(18, Suppl.): Abst 5558.
186. Campos, S.M., Dizon, D.S., Cannistra, S.A. et al. Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and mullerian cancers. J Clin Oncol 2007, 25(18, Suppl.): Abst 5517.
187. Belau, A., Pfisterer, J., Wimberger, P. et al. Randomized, mulitcenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 2007, 25(18, Suppl.): Abst 5556.
188. Vasey, P.A., Paul, J., Rustin, G. et al. Maintenance erlotinib (E) following first-line treatment with docetaxel, carboplatin and erlotinib in patients with ovarian carcinoma. J Clin Oncol 2007, 25(18, Suppl.): Abst 5560.
189. Konner, J.A., Fallon, K., Pezzuli, S. et al. A phase II study of intravenous (IV) and intraperitoneal (IP) paclitaxel (Tax), IP cisplatin (Cis), and TV bevacizumab (Bev) as first-line chemotherapy for optimal stage II or III ovarian, primary peritoneal, and fallopian tube cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 5523.
190. Welch, S., Hirte, H.W., Carey, M.S. et al. UCN-01 in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium. Gynecol Oncol 2007, 106(2): 305.
191. Kindler, H.L., Niedzwiecki, D., Hollis, D. et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J Clin Oncol 2007, 25(18, Suppl.): Abst 4508.
192. Dhillon, N., Aggarwal, B.B., Newman, R.A. et al. Curcumin and pancreatic cancer: Phase II clinical trial experience. J Clin Oncol 2007, 25(18, Suppl.): Abst 4599.
193. Brell, J.M., Matin, K., Evans, T. et al. Phase II study of gefitinib and docetaxel for patients (pts) with advanced pancreatic adenocarcinoma (APC) progressing after first-line therapy: Final results. J Clin Oncol 2007, 25(18, Suppl.): Abst 4586.
194. Wallace, J.A., Locker, G., Nattam, S. et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the university of Chicago phase II consortium. J Clin Oncol 2007, 25(18, Suppl.): Abst 4608.
195. Yoshitomi, H., Togawa, A., Kimura, F., Shimizu, H., Yoshidome, H., Miyazaki, M. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur (UFT) and gemcitabine (GEM) vs. gemcitabine alone in patients with resected pancreatic cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4542.
196. Astsaturov, I.A., Meropol, N.J., Alpaugh, R.K. et al. A randomized phase II and coagulation study of bevacizumab alone or with docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. J Clin Oncol 2007, 25(18, Suppl.): Abst 4556.
197. Kim, G.P., Oberg, A.L., Foster, N.R. et al. Phase II trial of bevacizumab, gemcitabine, oxaliplatin in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol 2007, 25(18, Suppl.): Abst 4553.
198. Nugent, F.W., Cunningham, C., Barve, M.A. et al. Phase 2 study of talabostat/gemcitabine in stage IV pancreatic cancer. J Clin Oncol 2007, 25(18, Suppl): Abst 4616.
199. Pautier, P., Joly, F., Kerbrat, P. et al. Gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal peritoneal adenocarcinoma: Final results of phase II study. J Clin Oncol 2007, 25(18, Suppl.): Abst 5566.
200. Sorensen, J.B., Sundstorm, S., Perell, K., Thielsen, A.-K. Pemetrexed second-line treatment in malignant pleural mesothelioma (MPM) following platinum-based first-line treatment. Ann Oncol 2006, 17(Suppl. 9): Abst 722PD.
201. Jassem, J., Ramlau, R., Santoro, A. et al. A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (pts) with advanced malignant pleural mesothelioma (MPM). Ann Oncol 2006, 17(Suppl. 9): Abst 7150.
202. Nelson, J.B., Chin, J.L., Love, W. et al. Results of a phase III randomized controlled trial of the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer (HRPC). J Clin Oncol 2007, 25(18, Suppl.): Abst 5018.
203. Mathew, P., Pettaway, C., Pisters, L., Williams, D., Troncoso, P., Logothetis, C. Preoperative platelet-derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation in high-risk localized prostate cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 5141.
204. Boccardo, F., Rubagotti, A., Tacchini, L. et al. Gefitinib (G) plus prednisone (P) versus placebo (pl) plus prednisone in the treatment of hormone-refractory prostate cancer (HRPC): A randomized phase II trial. J Clin Oncol 2007, 25(18, Suppl.): Abst 5070.
205. Ayala, G., Satoh, T., Li, R. et al. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006, 13(4): 716.
206. Hussain, M., Dunn, R., Rathkopf, D. et al. Suberoylanilide hydroxamic acid (vorinostat) post chemotherapy in hormone refractory prostate cancer (HRPC) patients (pts): A phase II trial by the prostate cancer clinical trials consortium (NCI 6862). J Clin Oncol 2007, 25(18, Suppl.): Abst 5132.
207. Chi, K.N., Hotte, S.J., Yu, E. et al. A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC). J Clin Oncol 2007, 25(18, Suppl.): Abst 5069.
208. Karavasilis, V., Mita, A., Hudes, G. et al. Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC). J Clin Oncol 2007, 25(18, Suppl.): Abst 5135.
209. Willett, C., Duda, D., Boucher, Y. et al. Phase I/II study of neoadjuvant bevacizumab with radiation therapy and 5-fluorouracil in patients with rectal cancer: Initial results. J Clin Oncol 2007, 25(18, Suppl.): Abst 4041.
210. Hong, Y.S., Kim, D.Y., Lee, K.S. et al. Phase II study of preoperative chemoradiation (CRT) with cetuximab, irinotecan and capecitabine in patients with locally advanced resectable rectal cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4045.
211. Bang, Y., Kang, Y., Kang, W. et al. Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer. Eur J Cancer Suppl 2007, 5(4): Abst 3542.
212. Iqbal, S., Goldman, B., Lenz, H.J., Fenoglio-Preiser, C.M., Blanke, C.D. SO413: A phase II SWOG study of GW572016 (lapatinib) as first line therapy in patients (pts) with advanced or metastatic gastric cancer. J Clin Oncol 2007, 25(18, Suppl.): Abst 4621.
213. Williams, A.R., Critchley, H.O., Osei, J. et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007, 22(6): 1696.
214. Kreitman, R.J., Wilson, W.H., Stetler-Stevenson, M., Noel, P., Fitzgerald, D.J., Pastan, I. Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia. J Clin Oncol 2007, 25(18, Suppl.): Abst 7095.
215. Zinzani, P.L., Musuraca, G., Tani, M. et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol 2007, 25(27): 4293.
216. Fruehauf, S., Klaus, J., Huesing, J. et al. Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma. Bone Marrow Transplant 2007, 39(12): 743.
217. Pappert, E.J. Botulinum toxin type B in type A resistant versus responsive subjects with cervical dystonia: A long-term open-label extension safety and efficacy study (AN072-351). Mov Disord 2006, 21(Suppl. 15): Abst P251.
218. Kasteleijn-Nolst Trenite, D.G., Genton, P., Parain, D. et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007, 69(10): 1027.
219. Lin, P.Y., Su, K.P. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007, 68(7): 1056.
220. Safarinejad, M.R. Safety and efficacy of escitalopram in the treatment of premature ejaculation: A double-blind, placebo-controlled, fixed-dose, randomized study. J Clin Psychopharmacol 2007, 27(5): 444.
221. Mu, Q., Johnson, K., Morgan, P.S. et al. A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophr Res 2007, 94(1-3): 332.
222. Yoo, H.K., Choi, S.H., Park, S., Wang, H.R., Hong, J.P., Kim, C.Y. An open-label study of the efficacy and tolerability of aripiprazole for children and adolescents with tic disorders. J Clin Psychiatry 2007, 68(7): 1088.
223. Gittelman, M., Swift, S., Forero-Schwanhaeuser, S. et al. Solifenacin treatment in patients reporting severe symptom bother while taking tolterodine: Effects on patient-reported outcomes. Neurourol Urodyn 2007, 26(5): Abst 130.
224. Chapple, C.R., Drogendijk, T., Wright, D.M., Bolodeoku, J. Responses to solifenacin in patients >65 years and ≥65 years with overactive bladder syndrome: Post-hoc results from the randomised, double-blind STAR study. Urology 2007, 70(Suppl. 3A): Abst POS-01.134.
225. Lucente, V., Ostergard, D., Davila, G.W., Forero-Schwanhaeuser, S. Patient-reported outcomes in 3 cohorts of patients defined by length of time as acute or chronic overactive bladder: An analysis of more than 2200 patients in the vesicare open-label trial (VOLT). Neurourol Urodyn 2007, 26(5): Abst 131.
226. Provenzano, R., Besarab, A., Macdougall, I.C. et al. The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: Results of a phase II study. Clin Nephrol 2007, 67(5): 306.
227. Morley, P., Bishop, J., Anderson, R. et al. Pulmonary delivery of the parathyroid hormone analogue Ostabolin-C stimulates markers of bone formation in postmenopausal women. J Bone Miner Res 2007, 22(Suppl. 1): Abst S421.
228. Denes, B., Bantchev, A.V., Karanikolov, S.S. et al. The efficacy, duration of the efficacy and safety of ozarelix, a novel GnRH antagonist, in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Urology 2007, 70(Suppl. 3A): Abst MP-20.02.
229. Oedekoven, C., Martinot, J.B., Langan, J., Engelstatter, R. Patients with stable asthma are well maintained with ciclesonide 160 mcg/d after switching from fluticasone propionate 500 mcg/d. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A188.
230. Chuchalin, A.G., Tsoi, A.N., Richter, K. et al. Safety and tolerability of indacaterol in asthma: A randomized, placebo-controlled 28-day study. Respir Med 2007, 101(10): 2065.
231. Wenzel, S., Busse, W., Calhoun, W. et al. The safety and efficacy of zileuton controlled-release tablets as adjunctive therapy to usual care in the treatment of moderate persistent asthma: A 6-month randomized controlled study. J Asthma 2007, 44(4): 305.
232. Ishii, M., Teramoto, S., Yamamoto, H., Yamaguchi, Y., Hanaoka, Y., Ouchi, Y. The pre-inhalation of a short acting beta-adrenergic agent (SABA), procaterol hydrochloride, ameliorates dry mouth side effects following tiotropium inhalation in patients with COPD. Am J Respir Crit Care Med 2007, 175(Abstracts Issue): A128.
233. Singh, D., Brooks, J., Hagan, G., O' Connot, B.J. Superiority of the 'triple' therapy of salmeterol/fluticasone propionate (SFC) and tiotropium (TIO) vs individual components in COPD. Eur Respir J 2007, 30(Suppl. 51): Abst 1298.
234. Stolk, J., Stockley, R.A., Rames, A., Rutman, O., Soliman, S. REPAIR II: Retinoid treatment of emphysema patients on the alpha-1-antitrypsin international registry. Eur Respir J 2007, 30(Suppl. 51): Abst 1293.
235. Oppel, T., Pavicic, T., Kamann, S., Brautigam, M., Wollenberg, A. Pimecrolimus cream (1%) efficacy in perioral dermatitis -Results of a randomized, double-blind, vehicle-controlled study in 40 patients. J Eur Acad Dermatol Venereol 2007, 21(9): 1175.
236. Fujita, W.H., McCormick, C.L., Parneix-Spake, A. An exploratory study to evaluate the efficacy of pimecrolimus cream 1% for the treatment of pityriasis alba. Int J Dermatol 2007, 46(7): 700.
237. Turpie, A.G.G., Eikelboom, J. Effect of fondaparinux 2.5 mg once daily on all cause mortality: A meta-analysis of thromboprophylaxis trials. Eur Heart J 2007, 28(Suppl. 1): 188.
238. Ruiz, J.C., Sanchez, A., Rengel, M. et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: Preliminary results of the EVERODATA registry. Transplant Proc 2007, 39(7): 2157.
239. Mzayek, F., Deng, H., Mather, F.J. et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2007, 2(1): e6.
240. Schwartz, J.I., Larson, P.J., Miller, J., Royalty, J., Wagner, J.A. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. Ann Rheum Dis 2007, 66(Suppl. 2): Abst SAT0381.
241. Edholm, T., Levin, F., Schmidt, P.T., Hellstrom, P.M., Naslund, E. The effects of ghrelin on proximal and distal gastric emptying and metabol control in healthy volunteers. Gastroenterology 2007, 132(4, Suppl. 2): Abst T1906.
242. Leroux-Roels, I., Borkowski, A., Vanwolleghem, T. et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial. Lancet 2007, 370(9587): 580.
243. Andrews, J., Honeybourne, D., Ashby, J. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother 2007, 60(3): 677.
244. Doberer, D., Gschwandtner, M., Mosgoeller, W., Bieglmayer, C., Heinzl, H., Petkov, V. Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects. Eur J Clin Invest 2007, 37(8): 665.
245. Horwitz, M.J., Tedesco, M.B., Sereika, S.M. et al. Safety and tolerability of subcutaneous PTHrP(1-36) in healthy human volunteers: A dose escalation study. Osteoporos Int 2006, 17(2): 225.
246. Lieu, H.D., Shryock, J.C., von Mering, G.O. et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nucl Cardiol 2007, 14(4): 514.
247. Goveia, M.G., Stek, J.E., Rodriguez, Z. et al. Concomitant use of an oral live pentavalent human-bovine reassortant rotavirus vaccine with licensed parenteral pediatric vaccines in the United States. Pediatr Infect Dis J 2007, 26(3): 221.
248. Brun, H., Thaulow, E., Fredriksen, P.M., Holmstrom, H. Treatment of patients with Eisenmenger's syndrome with Bosentan. Cardiol Young 2007, 17(3): 288.